Kaynak Hakan, Kaynak Derya, Gözükirmizi Erbil, Guilleminault Christian
Department of Neurology, Sleep Disorders Unit, Cerrahpasa Medical School, University of Istanbul, Cerrahpasa, 34303 Istanbul, Turkey.
Sleep Med. 2004 Jan;5(1):15-20. doi: 10.1016/j.sleep.2003.06.006.
To evaluate the effects of trazodone on subjective and objective measures of sleep in depressed insomnia patients treated with selective serotonin reuptake inhibitors (SSRIs). SSRIs can exacerbate or cause new insomnia while alleviating other symptoms of depression. Trazodone has been reported to be an effective hypnotic for patients with antidepressant-associated insomnia.
Twelve female patients were given either 100 mg trazodone or placebo for 7 days in a double-blind crossover design with a 7-day washout period. Polysomnographic recordings were repeated on the 3rd, 9th and 17th, 23rd nights after treatment with trazodone or placebo. Sleep was assessed by Pittsburgh sleep quality index (PSQI) at the beginning and end of the study. Psychological evaluation was done by Hamilton depression rating scale (HDRS).
Trazodone significantly increased total sleep time, percentage of stages 3+4, sleep efficiency index, sleep continuity index and decreased percentage of stage 1, number of awakenings, stage shifts compared to the baseline. This improvement was also obtained after 7 days of treatment. The PSQI score was reduced to 5+/-1.6 at the end of the study. HDRS was reduced to 11.5+/-4.5 with trazodone and to 12.2+/-3 with placebo.
Trazodone is effective in the treatment of antidepressant-associated insomnia.
评估曲唑酮对接受选择性5-羟色胺再摄取抑制剂（SSRI）治疗的抑郁性失眠患者睡眠主观及客观指标的影响。SSRI在缓解抑郁其他症状的同时，可能会加重或引发新的失眠。据报道，曲唑酮对伴有抗抑郁药相关性失眠的患者是一种有效的催眠药。
12名女性患者采用双盲交叉设计，给予100毫克曲唑酮或安慰剂，为期7天，洗脱期为7天。在使用曲唑酮或安慰剂治疗后的第3、9、17、23晚重复进行多导睡眠图记录。在研究开始和结束时，采用匹兹堡睡眠质量指数（PSQI）评估睡眠情况。通过汉密尔顿抑郁评定量表（HDRS）进行心理评估。
与基线相比，曲唑酮显著增加了总睡眠时间、3+4期睡眠百分比、睡眠效率指数、睡眠连续性指数，并降低了1期睡眠百分比、觉醒次数、睡眠阶段转换次数。治疗7天后也取得了这种改善。研究结束时，PSQI评分降至5±1.6。使用曲唑酮时HDRS降至11.5±4.5，使用安慰剂时降至12.2±3。
曲唑酮对治疗抗抑郁药相关性失眠有效。
